{"nctId":"NCT00790205","briefTitle":"Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)","startDateStruct":{"date":"2008-12-10","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":14671,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sitagliptin","otherNames":["MK-0431","JanuviaÂ®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has T2DM\n* Has HbA1c between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of antihyperglycemic agent(s), including insulin\n* Has pre-existing cardiovascular disease\n\nExclusion Criteria:\n\n* Has a history of type 1 diabetes mellitus or ketoacidosis.\n* Is not able to take sitagliptin","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)","description":"Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)","description":"Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)","description":"CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)","description":"CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Incidence of All-cause Mortality (Per Protocol Population)","description":"Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Incidence of All-cause Mortality (Intent to Treat Population)","description":"Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)","description":"Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)","description":"Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Renal Function Over Time (Per Protocol Population)","description":"Change in renal function based on estimated glomerular filtration rate \\[eGFR\\] using the Modification of Diet in Renal Disease \\[MDRD\\] method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"14.2"},{"groupId":"OG001","value":"-0.8","spread":"14.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"14.9"},{"groupId":"OG001","value":"-0.9","spread":"15.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"15.8"},{"groupId":"OG001","value":"-0.5","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"17.9"},{"groupId":"OG001","value":"-1.7","spread":"17.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"18.0"},{"groupId":"OG001","value":"-1.6","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"18.3"},{"groupId":"OG001","value":"-2.8","spread":"18.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"18.2"},{"groupId":"OG001","value":"-6.4","spread":"17.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Renal Function Over Time (Intent to Treat Population)","description":"Change in renal function based on eGFR using the MDRD method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"14.3"},{"groupId":"OG001","value":"-0.8","spread":"14.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"14.8"},{"groupId":"OG001","value":"-0.9","spread":"15.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"15.8"},{"groupId":"OG001","value":"-0.5","spread":"16.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"17.9"},{"groupId":"OG001","value":"-1.7","spread":"17.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"18.1"},{"groupId":"OG001","value":"-1.6","spread":"18.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"18.4"},{"groupId":"OG001","value":"-2.8","spread":"18.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"17.4"},{"groupId":"OG001","value":"-5.7","spread":"17.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c Over Time (Per Protocol Population)","description":"HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.8"},{"groupId":"OG001","value":"0.1","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.9"},{"groupId":"OG001","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"},{"groupId":"OG001","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.0"},{"groupId":"OG001","value":"0.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.1"},{"groupId":"OG001","value":"0.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.1"},{"groupId":"OG001","value":"0.1","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c Over Time (Intent to Treat Population)","description":"HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.8"},{"groupId":"OG001","value":"0.1","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.9"},{"groupId":"OG001","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"},{"groupId":"OG001","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.0"},{"groupId":"OG001","value":"0.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.1"},{"groupId":"OG001","value":"0.1","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.1"},{"groupId":"OG001","value":"0.1","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)","description":"Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"27.7"},{"groupId":"OG001","value":"-1.4","spread":"24.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"38.5"},{"groupId":"OG001","value":"0.2","spread":"45.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"27.7"},{"groupId":"OG001","value":"1.2","spread":"33.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"34.0"},{"groupId":"OG001","value":"3.2","spread":"31.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"24.0"},{"groupId":"OG001","value":"4.0","spread":"31.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"15.2"},{"groupId":"OG001","value":"1.5","spread":"25.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"10.1"},{"groupId":"OG001","value":"4.8","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)","description":"Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"27.5"},{"groupId":"OG001","value":"-1.4","spread":"24.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"39.4"},{"groupId":"OG001","value":"0.5","spread":"44.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"30.2"},{"groupId":"OG001","value":"1.2","spread":"32.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"33.1"},{"groupId":"OG001","value":"3.1","spread":"30.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"25.8"},{"groupId":"OG001","value":"3.9","spread":"30.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"16.3"},{"groupId":"OG001","value":"1.6","spread":"24.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"9.7"},{"groupId":"OG001","value":"6.4","spread":"16.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)","description":"Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)","description":"Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)","description":"In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent \\[AHA\\] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null},{"groupId":"OG001","value":"24.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)","description":"In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"27.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":928,"n":7266},"commonTop":[]}}}